pteridines has been researched along with Febrile Neutropenia in 1 studies
Febrile Neutropenia: Fever accompanied by a significant reduction in the number of NEUTROPHILS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Volasertib is a selective, potent cell-cycle kinase inhibitor that targets PLK to induce mitotic arrest and apoptosis." | 3.01 | Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. ( Borthakur, G; Cortes, J; Fagan, N; Kantarjian, H; Podoltsev, N; Rajeswari, S; Stahl, M; Taube, T; Uy, GL; Zeidan, AM, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortes, J | 1 |
| Podoltsev, N | 1 |
| Kantarjian, H | 1 |
| Borthakur, G | 1 |
| Zeidan, AM | 1 |
| Stahl, M | 1 |
| Taube, T | 1 |
| Fagan, N | 1 |
| Rajeswari, S | 1 |
| Uy, GL | 1 |
1 trial available for pteridines and Febrile Neutropenia
| Article | Year |
|---|---|
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Decitabine; Dose-Response | 2021 |